. 2024 Feb 7;49(6):716–731. doi: 10.1590/S1677-5538.IBJU.2023.0312

Supplementary Table 1. Association between PET parameters and pathological characteristics of ccRCC.

		⁶⁸Ga-PSMA-11 PET/CT								¹⁸F-FDG PET/CT
		SUV_max	P^a value	SUV_mean	P^a value	SUV_peak	P^a value	TLR	P^a value	SUV_max	P^a value	SUV_mean	P^a value	SUV_peak	P^a value	TLR	P^a value
Tumor necrosis			<0.001		0.016		0.026		0.017		0.119		0.057		0.107		0.241
	Negative	17.39		9.01		10.72		2.17		3.97		2.51		2.95		1.26
		7.58-25.20)		(4.04-13.68)		(5.39-18.44)		(1.32-3.93)		(2.98-6.40)		(1.82-3.48)		(2.33-4.95)		(1.04-1.96)
	Positive	30.51		15.39		20.79(16.91-23.47)		4.15		5.92		3.79		4.15		1.96
		(26.18-32.54)		(12.58-19.25)				(3.29-4.81)		(3.32-6.81)		(2.57-4.49)		(2.88-5.61)		(1.16-2.06)
Sarcomatoid or rhabdoid feature			<0.001		0.001		0.003		0.001		0.038		0.148		0.126		0.089
	Negative	18.76		10.23		13.91		2.64		4.02		2.69		3.44		1.26
		(8.91-26.93)		(5.06-13.21)		(6.85-19.35)		(1.50-4.03)		(3.03-6.79)		(1.83-4.05)		(2.34-5.38)		(1.04-2.06)
	Positive	33.93		15.67		20.80(19.74-22.74)		4.82		6.79		3.55		4.71		1.82
		(32.54-35.33)		(15.39-18.53)				(4.39-4.87)		(5.45-8.04)		(2.56-6.31)		(3.57-7.11)		(1.61-2.50)
Adverse pathology ^*			<0.001		0.001		0.001		0.001		0.049		0.055		0.079		0.15
	Negative	14.94		8.39		9.89		2.1		3.69		2.35		2.76		1.23
		(7.36-23.32)		(4.02-12.65)		(5.22-23.52)		(1.20-3.39)		(2.94-6.40)		(1.77-3.48)		(2.32-4.95)		(1.04-2.17)
	Positive	31.55		15.48		20.79		4.3		5.59		2.99		4.44		1.68
		(27.87-34.39)		(10.21-15.86)		(18.02-22.74)		(3.51-4.82)		(4.52-6.81)		(2.56-4.49)		(2.95-5.61)		(1.33-2.01)

Adverse pathology is defined as tumor presenting with necrosis or a sarcomatoid or rhabdoid feature

P values were calculated with Mann-Whitney U test

ccRCC = clear-cell renal cell carcinoma; SUV_max = maximal standard uptake value; SUV_mean = mean standard uptake value; SUV_peak = peak standard uptake value; TLR = tumor-to-liver standard uptake value ratio

Data are median (interquartile range) for SUV_max, SUV_mean, SUV_peak and TLR